Aurinia Pharmaceuticals Inc. (AUPH)
$
7.84
-0.15 (-1.91%)
Key metrics
Financial statements
Free cash flow per share
0.4609
Market cap
1.1 Billion
Price to sales ratio
4.4526
Debt to equity
0.2225
Current ratio
5.9317
Income quality
1.6134
Average inventory
42.7 Million
ROE
0.1077
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company based in Victoria, Canada, is dedicated to developing and commercializing therapies aimed at addressing various diseases with unmet medical needs, both in the United States and internationally. The company’s offering, LUPKYNIS, is specifically designed for the treatment of adult patients suffering from active lupus nephritis. In terms of financial performance, the income before tax ratio is 0.03 reflecting the pre-tax margin. Furthermore, the company incurred an income tax expense of $1,696,000.00 indicating its tax obligations. The total costs and expenses for the company are $239,820,000.00 reflecting its overall spending in pursuit of its therapeutic goals. The operating income ratio is -0.02 which indicates the company's operational profitability margin, highlighting its efficiency in generating income from its core operations. Additionally, the gross profit stands at $206,885,000.00 showcasing the company’s profitability derived from its primary activities. Aurinia's collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd emphasizes its strategic partnerships in advancing healthcare solutions. In the financial market, Aurinia Pharmaceuticals is viewed as an appealing option for investors. The stock is affordable at $7.99 making it suitable for budget-conscious investors. It boasts a high average trading volume of 1,400,592.00 indicating strong liquidity in the market, which enhances its attractiveness to potential buyers. With a market capitalization of $1,059,215,360.00 the company is classified as a small-cap player, positioning it uniquely within the market. As a key player in the Biotechnology industry, Aurinia contributes significantly to the overall market landscape, driving innovation and growth. The company operates within the Healthcare sector, which is instrumental in fostering advancements that can change the healthcare paradigm. This combination of strong liquidity, strategic positioning, and a clear focus on unmet medical needs underscores Aurinia Pharmaceuticals' role in shaping the future of biopharmaceuticals.
Is Aurinia Pharmaceuticals Inc. (AUPH) a good investment?
Investing in Aurinia Pharmaceuticals Inc. (AUPH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Aurinia Pharmaceuticals Inc. (AUPH)'s stock forecast?
Analysts predict Aurinia Pharmaceuticals Inc. stock to fluctuate between $5.15 (low) and $10.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aurinia Pharmaceuticals Inc.'s market capitalization?
As of 2025-05-30, Aurinia Pharmaceuticals Inc.'s market cap is $1,059,215,360, based on 135,104,000 outstanding shares.
How does Aurinia Pharmaceuticals Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Aurinia Pharmaceuticals Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aurinia Pharmaceuticals Inc. (AUPH) stock?
To buy Aurinia Pharmaceuticals Inc. (AUPH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AUPH. Place an order (Market, Limit, etc.).
What is the best time to invest in Aurinia Pharmaceuticals Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Aurinia Pharmaceuticals Inc. stock ever split?
Aurinia Pharmaceuticals Inc.'s last stock split was 1:50 on 2013-11-08.
How did Aurinia Pharmaceuticals Inc. perform in the last earnings report?
Revenue: $235,133,000 | EPS: $0.04 | Growth: -107.41%.
Where can I find Aurinia Pharmaceuticals Inc.'s investor relations reports?
Visit https://www.auriniapharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aurinia Pharmaceuticals Inc.?
You can explore historical data from here
What is the all-time high and low for Aurinia Pharmaceuticals Inc. stock?
All-time high: $33.97 (2021-11-03) | All-time low: $4.07 (2022-12-28).
What are the key trends affecting Aurinia Pharmaceuticals Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
businesswire.com
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis.
seekingalpha.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Andrea Christopher - Corporate Communications and IR Peter Greenleaf - President and CEO Joe Miller - CFO Greg Keenan - CMO Conference Call Participants Stacy Ku - TD Cowen Maury Raycroft - Jefferies Joseph Schwartz - Leerink Partners Olivia Brayer - Cantor Fitzgerald Sahil Dhingra - RBC Capital Markets David Martin - Bloom Burton Operator Greetings, and welcome to the Aurinia Pharmaceuticals Inc. Q1 2025 Earnings Call. At this time, all participants are in a listen-only mode.
businesswire.com
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025.
businesswire.com
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025.
seekingalpha.com
AUPH has seen some management changes, but activist investors demand more despite steady Lupkynis sales growth. The first quarter was strong in terms of sales in 2023 and 2024, and upcoming Q1 '25 earnings represent an opportunity to confirm that trend. AUPH is also expected to report the first clinical data from AUR200 in Q2 '25, which might allow the opportunity for the company to one day grow beyond revenues from Lupkynis.
247wallst.com
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.
benzinga.com
On Thursday, Aurinia Pharmaceuticals Inc AUPH reported fourth-quarter earnings of 1 cent per share, compared to a loss of 19 cents a year ago and the consensus loss of 2 cents.
seekingalpha.com
AUPH's Lupkynis showed modest revenue growth from Q2'24 to Q3'24, but limited sales growth going from Q2 to Q3 has been seen previously. Full-year 2024 net product revenue guidance of $210M-$220M appears achievable, with $158.6M already reported and Q4 typically outperforming Q3. Potential competitors in lupus nephritis and even in systemic lupus erythematosus include Roche and Biogen.
zacks.com
Aurinia (AUPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
See all news
